LifeCell (US) gets closer to off-the-shelf skin:
This article was originally published in Clinica
LifeCell (US) has moved closer to its goal of an off-the-shelf, full-thickness skin graft following the first animal study of cultured keratinocytes on its AlloDerm dermal graft. The company grafted a composite skin comprising AlloDerm and cultured neonatal foreskin keratinocytes onto full-thickness wounds on mice. The study showed that the human keratinocytes grew in immunocompromised mice only when co-cultured onto AlloDerm prior to grafting, according to the company.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.